• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Actelion Ltd - Product Pipeline Review - H2 2011 Product Image

Actelion Ltd - Product Pipeline Review - H2 2011

  • Published: November 2011
  • Region: Global
  • 88 pages
  • Global Markets Direct

Actelion Ltd – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Actelion Ltd - Product Pipeline Review - H2 2011” provides data on the Actelion Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Actelion Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from Actelion Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Actelion Ltd - Brief Actelion Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Actelion Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
Actelion Ltd Snapshot
Actelion Ltd Overview
Key Information
Key Facts
Actelion Ltd – Research and Development Overview
Key Therapeutic Areas
Actelion Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Actelion Ltd – Pipeline Products Glance
Actelion Ltd – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Actelion Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Actelion Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Actelion Ltd – Drug Profiles
Antibiotic
Product Description
Mechanism of Action
R&D Progress
Cadazolid
Product Description
Mechanism of Action
R&D Progress
CRTH2 Antagonist
Product Description
Mechanism of Action
R&D Progress
Drug for Multiple sclerosis
Product Description
Mechanism of Action
R&D Progress
Macitentan
Product Description
Mechanism of Action
R&D Progress
Ponesimod
Product Description
Mechanism of Action
R&D Progress
S1P1 Agonist
Product Description
Mechanism of Action
R&D Progress
Selexipag
Product Description
Mechanism of Action
R&D Progress
Tezosentan
Product Description
Mechanism of Action
R&D Progress
Actelion Ltd – Pipeline Analysis
Actelion Ltd – Pipeline Products by Therapeutic Class
Actelion Ltd - Pipeline Products By Target
Actelion Ltd – Pipeline Products by Route of Administration
Actelion Ltd – Pipeline Products by Molecule Type
Actelion Ltd – Recent Pipeline Updates
Actelion Ltd - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Almorexant
Palosuran
Tezosentan
Ventavis + Sildenafil + Bosentan
Actelion Ltd – Company Statement
Actelion Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 30, 2003: Actelion Acquires Privately Held Axovan AG
Aug 30, 2005: Co Therix Receives Expanded Approval For Ventavis from the US FDA
Dec 29, 2004: Co Therix Receives Approval for Ventavis from the US FDA
Aug 29, 2011: Actelion Reports Results From Exploratory Phase II Study With Macitentan In Patients With Idiopathic Pulmonary Fibrosis
Nov 28, 2005: Bosentan Studies In Pulmonary Fibrosis Show No Effect On Primary Exercise Improvement Endpoint
Jan 28, 2011: GSK And Actelion Discontinue Clinical Development Of Almorexant
Sep 27, 2010: Actelion's CONSCIOUS-2 Study With Clazosentan Does Not Meet Primary Endpoint
Jun 27, 2008: GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
May 27, 2003: Ventavis receives a positive opinion from Committee of Proprietary Medicinal Products for the treatment of PAH
May 23, 2011: Actelion's New Crth2 Antagonist Meets Primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis
May 23, 2006: ATS Presentation Highlights Strong Rationale For A Morbidity/Mortality Study With Bosentan In Idiopathic Pulmonary Fibrosis (IPF)
Feb 23, 2009: GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd
Apr 22, 2010: Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension
Mar 22, 2005: Co Therix Launches Ventavis Inhalation solution, indicated for the treatment of PAH
Dec 21, 2009: Actelion Announces Phase III Study Results Of Almorexant (RESTORA 1) For The Treatment Of Sleep Disorders
Dec 20, 2007: Actelion Initiates Phase III Development Program Of Almorexant
Apr 20, 2001: Phase III Clinical Trial Of Veletri For The Treatment Of Acute Heart Failure Symptoms Does Not Meet Primary Efficacy Objective
Dec 19, 2007: Actelion Initiates A Phase III Study Of Actelion-1 In PAH To Demonstrate Morbidity/Mortality Benefits
Jan 19, 2005: Co Therix Selects Accredo Health, Inc. For the distribution of Ventavis
Dec 18, 2008: Eur 7 Million Grants Boost Trophos Cholesterol-Oxime Programs For ALS, MS And Other Neurodegenerative Diseases
Dec 17, 2007: Actelion Provides Update On Bosentan In Metastatic Melanoma
Jul 17, 2009: Actelion's PGI2 Receptor Agonist Demonstrates Efficacy In Pulmonary Arterial Hypertension Patients
Jul 17, 2006: Actelion And Roche Enter Into Autoimmune Disorder Collaboration
May 17, 2010: Actelion Announces Presentation Of Positive Phase II Results With Selexipag In Patients With Pulmonary Arterial Hypertension
Oct 14, 2003: Co Therix Inc. Receives the EU approval for Ventavis
Dec 13, 2005: CoTherix and Respironics Launch A New Portable Inhalation Device Of Ventavis
Dec 13, 2000: Actelion And Genentech Sign Licensing Agreement For Tracleer (bosentan) In The U.S.
Nov 13, 2008: Actelion'S First-In-Class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development
Nov 13, 2008: Actelion's First-In-Class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development
Nov 12, 2007: Actelion Initiates Phase III Study Of Pivlaz (clazosentan)
Oct 12, 2009: Actelion Announced The Beginning Of The Phase Iib Study Of Act-128800 In Patients With Multiple Sclerosis.
Jan 12, 2010: Actelion Receives Positive Vote From FDA's Endocrinologic And Metabolic Drugs Advisory Committee For Zavesca For Treatment Of Niemann-Pick type C Disease
Dec 11, 2006: Actelion Initiates A Comprehensive Phase III Of Actelion-1
Aug 10, 2009: Ventavis (Iloprost) in pulmonary arterial hypertension receives US approval for increased 20 mcg/ml strength formulation
Nov 09, 2010: Actelion Receives Approval For Zavesca For Reimbursement Under Ontario Public Drug Program
Oct 09, 2009: Actelion Ltd Announces Dose-Finding Phase IIb Study Started In Patients With Multiple Sclerosis
Jan 09, 2007: Actelion Ltd. Announces Successful Completion of its Cash Tender Offer for Shares of CoTherix, Inc.
Dec 08, 2009: Actelion's selective S1P1 receptor agonist moves into advanced clinical development in psoriasis - Phase IIb dose-finding study in multiple sclerosis already ongoing - Roche to leave S1P1 alliance following comprehensive portfolio review and prioritization
Mar 08, 2006: Co Therix Starts a Phase III Trial of Ventavis Inhalation solution in combination with sildenafil citrate
Oct 05, 2010: Actelion Receives FDA Approval For Additional In-Use Conditions For Use Of Veletri In Pulmonary Arterial Hypertension
Apr 05, 2005: Co Therix Enters into an agreement with Quadrant to develop an extended-release formulation of Ventavis Inhalation solution.
Sep 02, 2007: Actelion Ltd. Announces New Study Data Of Almorexant
Aug 02, 2011: Actelion's Selective S1P1 Receptor Agonist Ponesimod Successful In Mid-stage Trial For Multiple Sclerosis
Jun 01, 2005: Co Therix Starts A Phase II trial for Ventavis inhalation solution for expanded indication
Mar 01, 2010: BUILD-3 Study With Bosentan In Idiopathic Pulmonary Fibrosis Does Not Meet Primary Endpoint
Financial Deals Landscape
Actelion Ltd, Deals Summary
Actelion Ltd, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Actelion Acquires Rights Of Epoprostenol From GeneraMedix
Partnerships
Basilea Enters Into Distribution Agreement With Actelion
Actelion Extends Collaboration With Invida Pharmaceutical
Actelion Enters Into An Agreement With Medexus
TI Pharma Enters Into Co-Development Agreement With Actelion, Erasmus And Maastricht University
Nippon Shinyaku Enters Into Agreement With Actelion Pharmaceuticals
Roche Enters Into Co-Development Agreement With Actelion
Licensing Agreements
Nippon Shinyaku Signs Licensing Agreement With Actelion
GlaxoSmithKline Enters Into An Agreement With Actelion
Actelion Enters Into Licensing Agreement With Nippon Shinyaku For Japan
Actelion Extends Licensing Agreement With Celltech For Zavesca
Debt Offering
Actelion Pharmaceuticals Completes Public Offering Of Convertible Bonds For $368 Million
Acquisition
Actelion Pharmaceuticals To Acquire Trophos
Actelion Acquires CoTherix
Cerep Acquires Hesperion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Actelion Ltd – Pipeline by Therapy Area and Indication, H2 2011
Actelion Ltd – Pipeline by Stage of Development, H2 2011
Actelion Ltd – Monotherapy Products in Pipeline, H2 2011
Actelion Ltd – Phase III, H2 2011
Actelion Ltd - Phase II, H2 2011
Actelion Ltd - Phase I, H2 2011
Actelion Ltd - Pipeline By Therapeutic Class, H2 2011
Actelion Ltd - Pipeline By Target, H2 2011
Actelion Ltd – Pipeline By Route of Administration, H2 2011
Actelion Ltd – Pipeline By Molecule Type, H2 2011
Actelion Ltd – Recent Pipeline Updates, H2 2011
Actelion Ltd - Discontinued Pipeline Products, 2010
Actelion Ltd, Subsidiaries
Actelion Ltd, Deals Summary
Actelion Acquires Rights Of Epoprostenol From GeneraMedix
Basilea Enters Into Distribution Agreement With Actelion
Actelion Extends Collaboration With Invida Pharmaceutical
Actelion Enters Into An Agreement With Medexus
TI Pharma Enters Into Co-Development Agreement With Actelion, Erasmus And Maastricht University
Nippon Shinyaku Enters Into Agreement With Actelion Pharmaceuticals
Roche Enters Into Co-Development Agreement With Actelion
Nippon Shinyaku Signs Licensing Agreement With Actelion
GlaxoSmithKline Enters Into An Agreement With Actelion
Actelion Enters Into Licensing Agreement With Nippon Shinyaku For Japan
Actelion Extends Licensing Agreement With Celltech For Zavesca
Actelion Pharmaceuticals Completes Public Offering Of Convertible Bonds For $368 Million
Actelion Pharmaceuticals To Acquire Trophos
Actelion Acquires CoTherix
Cerep Acquires Hesperion

List of Figures
Actelion Ltd – Pipeline by Therapy Area and Indication, H2 2011
Actelion Ltd – Pipeline by Stage of Development, H2 2011
Actelion Ltd – Monotherapy Products in Pipeline, H2 2011
Actelion Ltd – Pipeline By Therapeutic Class, H2 2011
Actelion Ltd - Pipeline By Target, H2 2011
Actelion Ltd – Pipeline By Route of Administration, H2 2011
Actelion Ltd – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS